drugset / Trial / NCT06463171
Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer
Phase 2
Unknown
60 enrolled
Shanghai Pulmonary Hospital, Shanghai, China
Shanghai Zhongshan Hospital · collabThe First Affiliated Hospital of Xiamen University · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to test in Locally Advanced or Metastatic Non-small Cell Lung Cancer patients with EGFR Mutations. The main question it aims to answer is: Evaluation of the Efficacy and Safety of Aumolertinib in Combination with Lastet for the Treatment of EGFR-Mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer in First-line Therapy. Participants will be treated with a combination of Aumolertinib and Lastet.
Timeline
- Start
- 2024-06
- Primary completion
- 2026-06
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Almonertinib | Small molecule | 110 mg | Oral |
| Subject | Etoposide | Small molecule | 50 mg | Oral |